Startup’s AI product set for wide distribution via major imaging vendor

One of the biggest imaging OEMs is offering healthcare providers using its radiography systems a third party’s AI toolset for detecting lung abnormalities.

GE Healthcare announced the move June 18, stating the software uses commercially available algorithms developed and marketed by Korea-based Lunit as Insight CXR.

The technology, which gained CE certification last fall, automatically flags signs of eight deviations from the norm. These include COVID-19 and related pneumonias as well as TB, lung nodules, pleural effusions and other diagnoses.

Calling the product Thoracic Care Suite, GE says providers using its global fixed, mobile and radiography/fluoroscopy systems can implement the toolset without engaging in any enterprise IT projects.

GE says its collaboration with Lunit is one of the first team-ups it knows of to bring commercially available AI products from a medical AI startup to an existing x-ray OEM.

The announcement quotes a professor from the University of Oxford and comes less than a week after that institution announced a partnership with GE Healthcare. In that endeavor the organizations are using AI to predict disease severity in COVID patients.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.